Posttransplant cyclophosphamide‐based anti–graft‐vs‐host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen‐mismatched unrelated donors versus haploidentical donors: A study on behalf of the <scp>ALWP</scp> of the <scp>EBMT</scp>

医学 危险系数 胃肠病学 环磷酰胺 内科学 累积发病率 移植 免疫抑制 免疫学 移植物抗宿主病 造血干细胞移植
作者
Arnon Nagler,Myriam Labopin,Mutlu Arat,Péter Reményi,Yener Koc,Didier Blaise,Emanuele Angelucci,Jan Vydra,Aleksandr Kulagin,Gerard Socié,Montserrat Rovira,Simona Sica,Mahmoud Aljurf,Zafer Gülbas,Nicolaus Kröger,Eolia Brissot,Zinaida Peric,Sebastian Giebel,Fabio Ciceri,Mohamad Mohty
出处
期刊:Cancer [Wiley]
标识
DOI:10.1002/cncr.34452
摘要

Background Both mismatched unrelated donor (MMUD) and haploidentical (haplo) transplantation are valid options in patients with high-risk acute lymphoblastic leukemia (ALL) lacking a matched donor. Methods The study compared the outcomes of adult patients with ALL in complete remission (CR) who underwent 9/10 MMUD versus haplo transplantation with posttransplant cyclophosphamide (PTCy) as graft-vs-host disease (GVHD) prophylaxis in 2010–2020. Results The study included 781 patients (MMUD, 103; haplo, 678). The median age was 40 (19–73) and 38 (18–75) years, respectively (p = .51). The most frequent immunosuppression agents added to PTCy were mycophenolate mofetil (MMF)/cyclosporine A and MMF/tacrolimus. In vivo T-cell depletion (anti-thymocyte globulin) was administered to 21% and 8% of the transplants, respectively (p < .0001). Neutrophil (absolute neutrophil count >0.5 × 109/L) recovery was achieved in 97.1% versus 96.7% versus (p = 1) in MMUD and haplo, respectively. Nonrelapse mortality and relapse incidence were not significantly different between MMUD and haplo, hazard ratio (HR) = 1.45 (95% confidence interval [CI], 0.81–2.62; p = .21) and HR = 0.81 (95% CI, 0.52–1.28, p = .38), respectively. HRs for leukemia-free survival, overall survival, and GVHD-free, relapse-free survival were respectively, HR = 1.05 (95% CI, 0.73–1.50, p = .8), HR = 1.17 (95% CI, 0.77–1.76, p = .46), and HR = 1.07 (95% CI, 0.78–1.46, p = .7) for haplo compared to MMUD. Acute (a)GVHD grade 2–4 was significantly higher with haplo, HR = 1.73 (95% CI, 1.08–2.76, p = .023), whereas aGVHD grade 3–4 and chronic GVHD did not differ significantly between the two transplant groups. Conclusion Outcomes of MMUD and haplo transplants with PTCy-based GVHD prophylaxis for ALL patients in CR are similar, apart from a higher incidence of aGVHD with haplo transplants.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘猛闯发布了新的文献求助10
1秒前
光亮慕凝完成签到,获得积分10
1秒前
szh123发布了新的文献求助10
1秒前
2秒前
2秒前
3秒前
乐乐应助机智谷蕊采纳,获得10
3秒前
6秒前
7秒前
8秒前
10秒前
11秒前
小马过河应助尼尼采纳,获得10
13秒前
13秒前
13秒前
吾将上下而求索完成签到,获得积分10
13秒前
13秒前
13秒前
科研通AI2S应助LIN采纳,获得10
14秒前
14秒前
14秒前
喜悦的半青完成签到,获得积分10
14秒前
15秒前
好宝宝发布了新的文献求助10
16秒前
上官若男应助程艳采纳,获得80
16秒前
伊可创发布了新的文献求助10
17秒前
Ava应助szh123采纳,获得10
18秒前
锦七发布了新的文献求助10
18秒前
小二郎应助收手吧大哥采纳,获得10
20秒前
21秒前
在水一方应助lm采纳,获得10
21秒前
可爱的函函应助jingjingA采纳,获得10
21秒前
Zdh同学完成签到,获得积分10
22秒前
我是老大应助淡然的铭采纳,获得10
23秒前
girl完成签到,获得积分10
24秒前
25秒前
华仔应助HAHAHA采纳,获得10
25秒前
25秒前
小坤同学发布了新的文献求助10
26秒前
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021